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Introduction
Infiltration of myeloid-derived cells in the glomerulus of the kid-
ney is a key pathogenic event in autoantibody-mediated glomeru-
lonephritis (GN), a leading cause of end-stage renal disease (1–4). 
Glomerular neutrophil accumulation occurs in Goodpasture’s (or 
anti–glomerular basement membrane [anti-GBM]) disease, infec-
tion-related GNs, and proliferative lupus nephritis (1–3). Neu-
trophils are one of the earliest leukocyte subsets to be recruited 
to deposited autoantibodies and are known to promote glomer-
ular injury (5). Yet, the molecular mechanisms driving immune 
complex–mediated (IC-mediated) neutrophil recruitment in the 
glomerulus, where capillaries are the major sites of leukocyte 
recruitment, remain poorly understood.
Low-affinity FcγRs, receptors for IgG that avidly bind ICs, 
are key determinants of leukocyte influx and injury following 
glomerular IgG deposition in models of proliferative GN. Mice 
deficient in the FcγR γ chain (γ–/–), essential for the expression 
and function of all murine activating FcγRs, exhibit a marked 
reduction in leukocyte accumulation and renal injury in acute 
and rapidly progressive anti-GBM antibody–induced GN, and 
in a lupus-prone NZB/W background (6, 7). The low-affinity 
activating FcγRs on neutrophils in mice and humans structural-
ly differ. Mice express FcγRIII and FcγRIV that rely on the FcγR 
γ chain, while humans express the uniquely human homologs 
FcγRIIA and FcγRIIIB, respectively. FcγRIIA has an immunoty-
rosine activating motif (ITAM) in its cytoplasmic domain, and 
is a mediator of destructive antibody-based inflammation in 
autoimmunity, while FcγRIIIB is a glycosylphosphatidylinosi-
tol-linked (GPI-linked) receptor whose physiological functions 
remain to be fully elucidated (8). Generation of mice express-
ing either of these human FcγRs selectively on neutrophils of 
γ–/– mice lacking their endogenous activating FcγRs allowed us 
to assess the role of the human FcγRs, and specifically FcγRs on 
neutrophils, in disease pathogenesis (9). The surface expres-
sion level of FcγRIIA on transgenic murine neutrophils and 
human neutrophils was comparable, while the surface expres-
sion level of FcγRIIIB on transgenic neutrophils was similar to 
that of FcγRIIA but lower than that on human neutrophils (9). 
Neutrophil human FcγRIIA or FcγRIIIB expression restored 
glomerular neutrophil influx in γ–/– mice following crescen-
tic anti-GBM–induced nephritis. However, only FcγRIIA sus-
tained neutrophil influx and promoted glomerular injury, 
suggesting that FcγRIIA on neutrophils is a key molecular link 
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Here, we explored the mechanisms driving neutrophil cap-
ture by immobilized ICs in vitro and assessed the physiological 
relevance of our findings by intravital microscopy and in a model 
of crescentic, anti-GBM nephritis. Using a large small-molecule 
screen on primary neutrophils, we identified the Abl/Src inhibitor 
bosutinib as the lead inhibitor of several FcγRIIA functions and 
both Abl1 and Src kinases as key mediators of FcγRIIA-mediated 
neutrophil capture on immobilized ICs under flow. Abl1 silencing 
or Src inhibition prevented FcγR-mediated F-actin polymerization, 
which was required for IC-mediated neutrophil capture. Biophysi-
cal approaches showed that FcγR binding to IgG was strengthened 
under mechanical force and required F-actin polymerization, 
which may enable rapid FcγR-mediated capture under flow. This 
between IC deposition, glomerular neutrophil recruitment, 
and end-organ damage (9). Studies in vitro suggest that neu-
trophils, via their own FcγRs, can be directly recruited to IgG: 
FcγRIIIB promoted the capture of human neutrophils to plate 
immobilized IgG-ICs under physiological flow conditions (10, 
11), while FcγRIIA supported the increase in neutrophil adhe-
sion to TNF-activated endothelial cells coated with antibodies 
(11). A direct interaction of FcγRs on circulating neutrophils 
with deposited IgG may be particularly relevant in the capillar-
ies of the glomerulus, as IgGs deposited in the GBM are poten-
tially accessible to circulating neutrophils via open endothelial 
fenestrae (12), as are anti–endothelial cell antibodies present 
in many glomerulonephritides (13).
Figure 1. A small-molecule screen identifies bosutinib as the lead inhibitor of FcγRIIA functions in neutrophils. (A) FcγRIIA+/γ–/– mouse bone marrow 
neutrophils (BMNs), suspended in fluorescent ROS probes with library compounds (light blue, at 10 μM), were loaded on BSA/anti-BSA IC–coated plates, 
and fluorescence was read 1 hour later. The Src inhibitor PP2 (red) and the diluent DMSO (vehicle, deep blue) were positive and negative controls, respec-
tively. A profile with representative “hits” (arrows) is shown. (B) Bosutinib (Bos) and PP2 at indicated doses were evaluated and plotted relative to vehicle 
(0 nM) (n = 3). (C) BMNs were preincubated with mouse anti–human FcγRIIA and then Bos, PP2, or vehicle (Veh). ROS generation was evaluated upon addi-
tion of F(ab′)2 anti-mouse IgG in a luminol-based assay. A representative profile is shown (left). The average peak level of ROS was normalized to vehicle 
(right) (n = 3). (D) Bos-pretreated BMNs were stimulated with PMA, and ROS generation was assessed as in C (n = 3). (E) The number of adherent (left) and 
spread (right) cells on BSA or IC under static conditions of BMNs pretreated with vehicle (–) or Bos (n = 3). (F) Adhesion under shear flow (0.5 dyn/cm2) to 
BSA- or IC-coated coverslips, of vehicle- or Bos-pretreated BMNs. The data are presented as the average fold induction normalized to the average value of 
the vehicle (–)/BSA control (n = 3). Neutrophils were treated with 100 nM Bos or 1 μM PP2 unless indicated otherwise (n = 3). Data are mean ± SEM.  
*P < 0.05, **P < 0.01, ***P < 0.001, 1-way ANOVA followed by Dunnett’s multiple comparison test for B and C to assess dose responsiveness of the drugs 
compared with vehicle, and for E and F.
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that leads to constitutively active Abl1 (19). Adhesion-dependent 
ROS generation (20), as occurs in the primary screen with plate-
bound ICs, also relies on the CD18 integrin Mac-1 (Supplemental 
Figure 1B). This is consistent with previous observations that Mac-
1 activation by FcγRs sustains neutrophil adhesion (21, 22), which 
in our case may occur following binding of activated Mac-1 to BSA 
(23) in the anti-BSA/BSA ICs. To discern the effects of bosutinib 
on FcγRIIA alone, ROS was evaluated after FcγRIIA cross-linking 
of neutrophils in suspension; bosutinib reduced ROS generation 
with an IC50 of 10–50 nM (Figure 1C) while having no effect on 
ROS generated after PMA treatment (Figure 1D), which directly 
activates the NADPH oxidase (24). FcγR engagement leads to the 
release of enzymes from granules (8) and neutrophil extracellular 
traps (NETs) (3, 25–27), a network of DNA fibers extruded by neu-
trophils. Bosutinib reduced FcγRIIA-mediated release of enzymes 
(Supplemental Figure 1C), albeit reduced cell adhesion may also 
contribute to these results. Bosutinib also inhibited IC-induced 
NET release but not receptor-independent NETosis induced by 
the calcium ionophore ionomycin (Supplemental Figure 1D).
Next, the effect of bosutinib on FcγR-dependent neutrophil 
adhesion to plate-bound ICs under static and physiological flow 
conditions was evaluated. Bosutinib reduced the adhesion and 
spreading of FcγRIIA+/γ–/– neutrophils on ICs under static condi-
tions (Figure 1E), which is both FcγR and Mac-1 dependent (21, 
22). Importantly, bosutinib significantly reduced FcγRIIA+/γ–/– 
neutrophil tethering to immobilized ICs under physiological flow 
(Figure 1F), which is strictly FcγR dependent (10, 11) and may serve 
as a surrogate for neutrophil accumulation following intravascular 
IC deposition. Similarly, human neutrophils treated ex vivo with 
bosutinib exhibited a significant reduction in FcγRIIA-mediated 
(but not PMA-mediated) ROS generation (IC50 of 1–5 nM) (Figure 
2, A and B), release of enzymes (Supplemental Figure 1E), adhe-
sion and spreading on ICs under static conditions (Figure 2C), and 
neutrophil capture on plate-bound ICs under flow (Figure 2D). 
Likewise, the Abl inhibitors imatinib and nilotinib, which, unlike 
bosutinib, do not affect Src activity (28), reduced human neutro-
phil FcγRIIA-mediated ROS generation (Figure 2B) and adhesion 
to ICs under static (Figure 2C) and flow (Figure 2D) conditions. 
This suggests that Abl proteins play a key role in these FcγR func-
tions. The Src kinase inhibitor PP2 also reduced ROS generation 
(Figure 2A) and neutrophil adhesion to ICs under static condi-
tions (Figure 2C) as expected (18). The aforementioned studies 
evaluating the capture of human neutrophils on immobilized ICs 
were largely dependent on FcγRIIIB (10, 11), which is GPI-linked 
but still signals via nonreceptor tyrosine kinase (29). To interro-
gate the effects of bosutinib specifically on FcγRIIA-mediated 
capture in human neutrophils, we evaluated neutrophil adhesion 
to TNF-activated human dermal microvascular endothelial cells 
(HDMECs) coated with ICs in situ, which results in an increase 
in neutrophil adhesion compared with TNF alone that is FcγRIIA 
and not FcγRIIIB dependent (11). As reported (11), ICs increased 
neutrophil adhesion to TNF-activated endothelial cells, which was 
abrogated by functional blocking anti-FcγRIIA but not anti-Fcγ-
RIIIB antibody (Figure 2E). Importantly, human neutrophil pre-
treatment with bosutinib or imatinib markedly reduced neutro-
phil adhesion on TNF-activated/IC-coated HDMECs to levels 
observed for endothelial cells treated with TNF alone (Figure 2E). 
mode of IC-mediated neutrophil capture was evident by intravital 
microscopy. Endogenous mouse neutrophils rapidly arrested in 
glomerular capillaries in response to anti-GBM deposition in the 
absence of prior rolling or crawling. Simultaneous adoptive trans-
fer of FcγR-deficient and FcγRIIA-expressing neutrophils or vehi-
cle-treated and bosutinib-treated neutrophils demonstrated the 
importance of FcγRIIA and Abl/Src in this process, respectively. 
Bosutinib treatment inhibited neutrophil accumulation and renal 
injury in mice subjected to crescentic anti-GBM nephritis, a model 
of Goodpasture’s syndrome (14). Thus, bosutinib, a drug currently 
used for the treatment of chronic myelogenous leukemia (CML) 
patients (15, 16), may be repurposed to inhibit IgG-mediated glo-
merular neutrophil accumulation, potentially one of the earliest 
steps in IgG-mediated renal inflammation.
Results
FcγRIIA-mediated neutrophil functions are inhibited by bosutinib, 
identified in a high-throughput screen. We established an auto-
mated, neutrophil reactive oxygen species–based (ROS-based) 
high-throughput drug screen in primary neutrophils for FcγRI-
IA inhibitors using plate-bound ICs (BSA and anti-BSA) and a 
small-molecule library in which FDA-approved drugs are highly 
represented (50%). Mature neutrophils isolated from γ–/– mice 
showed minimal H2O2 generation following their incubation with 
plate-bound ICs, while the same expressing human FcγRIIA (Fcγ-
RIIA+/γ–/–) gave a robust ROS response (Supplemental Figure 1A; 
supplemental material available online with this article; https://
doi.org/10.1172/JCI94039DS1). Next, the ability of library com-
pounds to inhibit FcγRIIA+/γ–/–-induced ROS was evaluated. Vehi-
cle control (DMSO) and PP2, an inhibitor of Src family tyrosine 
kinases known to signal downstream of FcγRs (17, 18), served as 
negative and positive controls, respectively. The screen of 8,483 
compounds yielded 84 hits (1% hit rate), defined as those that have 
an inhibitory potential of ≥95% of PP2 (Figure 1A). Of the 30 com-
pounds cherry-picked for a secondary screen (Table 1), the most 
potent was bosutinib, with an IC50 of 50–100 nM, which approxi-
mated that of PP2 (Figure 1B). Bosutinib is a dual Abl/Src inhibitor 
currently used in CML patients to inhibit Bcr-Abl, a fusion protein 
Table 1. List of top 10 biologically active compounds that 
significantly suppressed mouse bone marrow–derived neutrophil 
ROS generation induced by immobilized ICs
Compounds (1.1 μM) Mode of action ROS RLU ratio
Bosutinib Bcr-Abl and Src-Abl kinase inhibitor 0.033
A-443654 Akt inhibitor 0.266
PF431396 FAK and Pyk-2 inhibitor 0.301
GF109203X PKC inhibitor 0.338
BX795 PDK1 and TBK1 inhibitor 0.396
Chlorocresol Ryanodine Ca++ receptor activator 0.431
Lck inhibitor Lck inhibitor 0.462
Parachlorophenol Topical antibacterial 0.606
Cresol Antiseptic and disinfectant 0.761
Ro 31-8220 PKC inhibitor 0.778
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Figure 2. Bosutinib inhibits FcγRIIA functions in human neutrophils. (A) ROS after FcγRIIA cross-linking (XL) (left) or PMA (right) in bosu-
tinib-pretreated (Bos) and PP2-pretreated neutrophils as in Figure 1, C and D (n = 3). (B) Representative profile of XL-induced ROS after treatment 
with vehicle or 100 nM Bos, imatinib (Ima), or nilotinib (Nil) (n = 3). (C) Neutrophils pretreated with 100 nM of the indicated compounds, 1 μM 
PP2, or vehicle (DMSO, –) on BSA- or IC-coated plates, stained with fluorescent phalloidin, and quantitated for adherent cells (left) and spread 
cell area (right) (n = 3). Representative images are shown. Original magnification, ×600. (D) The number of adherent cells pretreated as in C and 
drawn across BSA- or IC-coated plates at 1.0 dyn/cm2 was calculated and is presented as the fold induction compared with vehicle (–)/BSA control 
(n = 3, except for Nil, n = 2). (E) HDMECs were treated without (–) or with (+) TNF and/or anti-CD105 plus a secondary antibody (2°ab). Neutrophils 
pretreated with anti-FcγRIIIB (3G8), FcγRIIA (IV.3), or isotype (Iso) controls (left panel), or with 100 nM Bos or Ima (right panel), were drawn across 
HDMECs at 1.5 dyn/cm2. The number of rolling and adherent cells was assessed. Fold induction was relative to untreated HDMECs (n = 3). (F) XL- or 
PMA-induced ROS in blood leukocytes from 3 CML patients receiving Bos and matched normal volunteers (Ctrl). A representative ROS profile (left 
panel) and average fold induction relative to the XL (Ctrl) sample (right panel) are shown (n = 3). (G) CML and control leukocytes were analyzed as in 
D at 1.0 and 1.5 dyn/cm2. Fold induction is relative to the control sample on BSA (Ctrl/BSA) (n = 3). All data are expressed as the mean ± SEM.  
*P < 0.05, **P < 0.01, 1-way ANOVA followed by Dunnett’s multiple comparisons test for A to assess dose responsiveness of the drugs compared 
with vehicle and also for C–E and G, and by 2-tailed unpaired t test in F.
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Thus, Abl/Src inhibition reduced FcγRIIA-mediated adhesion to 
ICs while sparing the classical adhesion cascade associated with 
TNF activation of the endothelium (30).
To determine whether bosutinib reduces FcγR-mediated activ-
ity when administered in vivo, FcγR functions were evaluated in 
neutrophils from CML patients receiving bosutinib. Total leuko-
cytes in peripheral blood of CML patients and matched normal vol-
unteers were evaluated immediately after red blood cell (rbc) lysis, 
as bosutinib’s effect on neutrophils is reversible over time (data 
not shown). The percentage of neutrophils and neutrophil FcγRIIA 
levels on the surface were similar between samples (Supplemental 
Figure 2, A and B). An 80% reduction in FcγRIIA-mediated ROS 
generation was observed in patients compared with normal volun-
teers, while PMA-induced ROS was similar in both groups (Figure 
2F). The interaction of neutrophils from bosutinib-treated patients 
with immobilized ICs under flow was significantly reduced com-
pared with the interaction of those from the normal donors (Figure 
2G). Neutrophils obtained from newly diagnosed, untreated CML 
patients exhibited a partial reduction in FcγRIIA-induced ROS gen-
eration compared with those from normal volunteers, albeit this 
was not significant (peak RLU: normal, 1.00 ± 0.83; CML patients, 
0.51 ± 0.43; n = 3 per group, P = 0.63).
FcγRIIA activation is initiated by ITAM phosphorylation, which 
triggers the docking of Syk and its phosphorylation by Src kinases 
that is followed by several downstream signals, including the phos-
phorylation and subsequent activation of the Rho GTPase guanine 
exchange factor Vav; Pyk-2 downstream of Syk; PI3K/Akt; MAPK/
ERK; and NADPH oxidase components such as p40phox (17, 18). 
Bosutinib inhibited FcγRIIA cross-linking–induced phosphorylation 
of these components as well as Crkl, a known Abl substrate (31) in 
FcγRIIA/γ–/– neutrophils (Supplemental Figure 3A). Similar results 
were obtained with human neutrophils (Supplemental Figure 3B).
Abl1 regulates F-actin polymerization needed for neutrophil Fcγ-
RIIA-mediated recruitment and force-induced enhancement of FcγRI-
IA interaction with IgG. To further interrogate Abl1’s contribution 
to FcγRIIA functions, we used differentiated human HL-60 cells, 
which are genetically tractable neutrophil-like cells that express 
FcγRIIA but have no detectable FcγRIIIB and low expression of 
CD18 integrins (ref. 11 and data not shown). Treatment with bosu-
tinib or other Bcr-Abl inhibitors significantly inhibited HL-60 cell 
interaction with ICs under flow (Figure 3A) as demonstrated for 
human neutrophils (Figure 2D). HL-60 cells were transduced with 
Abl1 shRNAs to 2 independent sequences that stably reduced Abl1 
protein compared with the shRNA control (Figure 3B). Both Abl1 
shRNAs significantly attenuated FcγRIIA-mediated ROS gener-
ation compared with control shRNA (Figure 3C), while PMA-in-
duced ROS was only partially affected (Figure 3C). Abl1 silencing 
reduced cell adhesion and spreading on ICs under static condi-
tions (Figure 3D), and markedly inhibited adhesion to ICs under 
flow (Figure 3E). Abl1-silenced cells exhibited a decrease in Fcγ-
RIIA-induced phosphorylation of Crkl but not Pyk-2, Vav, ERK1/2, 
and Akt (Figure 3F), suggesting that Abl1 was not essential for 
proximal FcγR-mediated signaling events. Thus, the reductions in 
signaling observed with bosutinib in human neutrophils (Supple-
mental Figure 3A) likely reflect its known targeting of Src and the 
STE20 serine/threonine kinases (28, 32).
Among tyrosine kinases, Abl kinases (Abl1 and the Abel-
son-related gene, Arg) are unique in being able to directly bind and 
regulate the polymerization of F-actin (33). FcγRIIA cross-linking 
increased actin polymerization within seconds in control shRNA 
HL-60 cells as assessed by FACS analysis of NBD-phallacidin–
stained cells (34). The maximal change in fluorescence intensity, 
which reflects actin polymerization (Figure 3G), was completely 
prevented in Abl1-silenced cells (Figure 3G) or following treatment 
with Bcr-Abl inhibitors (Figure 3H). The Src inhibitor PP2 similar-
ly inhibited F-actin polymerization (Figure 3H). F-actin polymer-
ization was required for FcγRIIA-mediated ROS generation and 
neutrophil capture by ICs under flow, with a greater requirement 
for F-actin in the latter. That is, treatment with cytochalasin D, an 
inhibitor of F-actin polymerization, partially reduced FcγRIIA-in-
duced ROS generation (RLU at peak: vehicle, 1,879 ± 971; 20 μM 
cytochalasin D, 1,037 ± 483), while it markedly inhibited HL-60 
tethering to plate-immobilized ICs (data not shown) as well as 
human neutrophil interaction with immobilized ICs (Figure 4A) 
or IC-coated HDMECs (Figure 4B) under flow. However, cytocha-
lasin D had no affect on neutrophil adhesion to ICs under static 
conditions (Figure 4C). Thus, polymerized actin was not required 
when the on-rate of FcγR-IgG binding was not limiting, as is the 
case under static conditions, while it was essential under shear 
flow, which is governed by the force-dependent off-rate of the 
FcγR-IgG interactions. This, together with the observed ability of 
FcγR to bind ICs under flow, prompted us to determine whether 
mechanical force increases FcγRIIA-IgG bond lifetimes, referred 
to as catch bonds (35), which we reasoned would facilitate capture 
of neutrophils under flow and may require F-actin polymerization. 
For this, Jurkat cells lacking CD18 integrins (36) were engineered 
to express FcγRIIA to evaluate the role specifically of this FcγR, 
in the absence of FcγRIIIB, in the aforementioned cell responses. 
FcγRIIA-expressing Jurkat cells bound ICs under flow, and cyto-
chalasin D reduced this binding (Figure 4D) without affecting cell 
binding to ICs under static conditions (Figure 4E). Importantly, 
using a biomembrane force probe, we demonstrated that FcγRIIA 
formed catch bonds with IgG at forces ranging from 5 to 25 pN, 
Figure 3. Role for Abl kinases in FcγRIIA-mediated neutrophil functions. 
(A) Differentiated HL-60 cells pretreated with vehicle (–), bosutinib (Bos), 
imatinib (Ima), nilotinib (Nil), or PP2 adherent to ICs or BSA under flow. 
Fold induction is relative to vehicle (–) on BSA (n = 3). (B) A representative 
Western blot of cells expressing Abl1 (Abl1 #01 and #00) or control shRNA 
and analyzed for Abl or β-actin (loading control) (n = 3). (C) ROS in cells in B 
subjected to FcγRIIA cross-linking (XL) or treated with PMA. The peak level 
was normalized to control shRNA cells (n = 3). (D) Cells on BSA- or IC-coat-
ed plates were stained for actin, and the number of adherent cells (left) 
and the area of a single spread cell (right) were calculated (n = 3, except 
in the right panel, n = 2 for treatment with shRNA #00). (E) Cell adhesion 
to BSA or IC at 0.35 dyn/cm2. Fold induction is relative to control cells on 
BSA (n = 3). (F) Western blot analysis of indicated proteins with or without 
FcγRIIA XL for times in seconds. β-Actin is the loading control. One repre-
sentative of 3 is shown. (G and H) F-actin polymerization analyzed by flow 
cytometry (mean fluorescence intensity, MFI) at indicated times after XL 
and staining with NBD-phallacidin. Omission of the primary antibody is 
the negative control. Shown is 1 representative of 3 experiments for Abl1- 
or control shRNA–expressing cells (G), and for cells treated with vehicle 
(–) or indicated inhibitors before XL (H). For A–H, cells were treated with 1 
μM of Bcr-Abl inhibitors or PP2, or 3 μM cytochalasin D (cytD). All data are 
mean ± SEM. *P < 0.05, **P < 0.01, 1-way ANOVA followed by Dunnett’s 
multiple comparison test for A and C–E.
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while at higher forces the catch bonds transitioned to slip bonds. 
Cytochalasin D treatment had no significant effect on bond life-
times at 0–8 pN force but markedly inhibited bond stabilization at 
higher mechanical forces (Figure 4F). Thus, FcγRIIA forms catch 
bonds with IgG, and this relies on F-actin polymerization.
Together, these data demonstrate that FcγRIIA induces 
F-actin polymerization via Abl1 and Src kinases and that F-actin 
polymerization supports force-induced FcγRIIA interactions with 
IgG, which may facilitate neutrophil capture by IgG under flow.
Rapid neutrophil capture within glomerular capillaries fol-
lowing anti-GBM antibody. We exploited 2-photon intravi-
tal microscopy to examine neutrophil behavior in the kidney 
under steady-state conditions and 1.5 hours after administra-
tion of rabbit nephrotoxic antisera, which leads to IgG deposi-
tion on the endothelium and GBM and will herein be referred 
to as anti-GBM antibody. We used LysM-GFP mice to evaluate 
endogenous neutrophils, focusing on early neutrophil–vessel 
wall interactions. Notably, neutrophils are readily distinguish-
able from monocytes and macrophages, as they are 5–10 times 
brighter than CD11b+, Ly6G– monocytes with the brightest GFP+ 
cells (>2 logs over background) being preferentially detected 
with our imaging settings. These cells are more than 95% neu-
trophils based on flow cytometric analysis (37, 38) and intravital 
microscopy analysis of LysM-GFP mice injected with a neutro-
phil-specific anti-Ly6G antibody (1A8) (Supplemental Figure 4, 
A–C). The right kidney was surgically exteriorized and imaged 
(39), and tissue perfusion was verified by bright-field observa-
tion of robust capillary flow and by injection of Q-dots into the 
retro-orbital sinus. In both control and anti-GBM–treated mice, 
neutrophils were visible passing through and arresting tran-
siently (“fluttering”) in glomerular capillaries, which we show 
approximated the diameter of a neutrophil (Figure 5, A and B). 
This “fluttering” behavior was also observed with small beads 
injected i.v. (data not shown), suggesting that hemodynamic 
flow variations in the tortuous glomerular capillary bed account 
for this behavior. Time-lapse recordings (13 frames per second) 
were taken for up to 20 minutes, and the number of arrest-
ed neutrophils at t = 0 and t = 9 minutes was counted in both 
groups. In control animals, a few arrested neutrophils were pres-
ent in glomeruli, but in anti-GBM–treated mice, these numbers 
increased significantly (Figure 5C). Neutrophil duration time 
was plotted for each group, and both distributions were clear-
Figure 4. Actin polymerization is required for force-induced FcγRIIA-mediated interaction with IgG. (A) Human peripheral blood neutrophils were treat-
ed with 2 different doses of cytochalasin D (cytD) or with DMSO (–), and adhesion of cells to an IC- or BSA-coated surface under flow (1.0 dyn/cm2) was 
assessed. Fold induction is relative to vehicle-treated (–) samples on ICs (n = 3). (B) Human peripheral blood neutrophils were pretreated with cytD and 
drawn across HDMECs treated with TNF and anti-endoglin as indicated and detailed in Figure 2E. Fold induction is relative to untreated HDMECs  
(n = 3). (C) Human neutrophils were treated with 2 different doses of cytD or vehicle (DMSO, –), and the number of cells adherent to IC- or BSA-coated 
surfaces under static conditions was assessed (n = 3). (D and E) Jurkat cells expressing FcγRIIA but mutagenized to lack CD18 integrins were evaluated 
for adhesion to ICs or BSA under flow (D) or static (E) conditions in the presence or absence of cytD (n = 3). Representative images for the static assay are 
shown to illustrate changes in actin distribution in cytD-treated versus vehicle-treated (–) neutrophils adherent to ICs. Scale bar: 25 μm. (F) Force-depen-
dent lifetimes of single bonds (in seconds) between hIgG1-immobilized beads and FcγRIIA-transfected Jurkat cells in the presence (blue circles) or absence 
(–, red squares) of cytD. Each point represents more than 30 repeated measurements. Data are expressed as mean ± SEM. *P < 0.05, **P < 0.01, 1-way 
ANOVA followed by Dunnett’s multiple comparison test for A–E and 2-tailed unpaired t test for F.
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increased proportion of adhesion events in this time period. The 
mean duration time increased in the anti-GBM group compared 
with control (Figure 5F), as did the median value (control, 36.09 
± 37.90 seconds; anti-GBM, 80.73 ± 17.40 seconds). The “stop 
and go” behavior of neutrophils in the glomerular capillaries 
(Supplemental Videos 1 and 2) was strikingly different from the 
slow neutrophil rolling and intraluminal crawling observed in 
larger vessels (20–30 μm) in other organs and inflammatory set-
tings (37, 38). Indeed, neutrophil crawling was observed infre-
quently, with rates of 4.29 ± 1.1 and 7.2 ± 2.24 cells per glomer-
ly non-normally distributed with many short duration events. 
Despite the qualitative similarities, neutrophils in the anti-GBM 
group had significantly increased duration times compared with 
those in the control group (2-tailed Mann-Whitney U, P < 0.01) 
(Figure 5D). We also compared the shape of the duration time 
distributions using a 2-sample Kolmogorov-Smirnov (KS) test 
(Figure 5E). The KS test comparison percentile plot showed that 
the duration time distributions were significantly different (P < 
0.01, D = 0.3813), with the plots diverging quickly at short dura-
tions (less than 60 seconds) and the anti-GBM group having an 
Figure 5. In vivo neutrophil trafficking in glomerular capillaries at steady state and after anti-GBM treatment in LysM-GFP mice. In vivo 2-photon time-
lapse imaging of glomeruli in untreated LysM-GFP mice at steady state (untreated, control) and 1.5–2 hours after anti-GBM (αGBM) treatment (n = 3 mice, 5 
glomeruli for control; n = 4 mice, 6 glomeruli for αGBM). Imaging parameters were set to preferentially visualize GFP+ neutrophils (see Supplemental Figure 
4A). (A and B) Glomerular capillaries (GC, red, Q-dot 565) and neutrophils (Np, green, LysM-GFP) in a control (left) and αGBM-treated (right) mouse are shown 
(A). Capillary lumen and neutrophil diameters were calculated and found to be similar in size with no significant differences between control and αGBM 
groups (B) by a 2-tailed unpaired t test. (C) The mean ± SEM of neutrophils per glomerulus (glm) (arrows) in untreated and αGBM-treated LysM-GFP mice 
were counted at 0 and 9 minutes, and representative images are shown. SHG, second-harmonic generation. Scale bars: 25 μm (A), 50 μm (C). (D) Distribu-
tions of glomerular duration times for control and αGBM groups plotted in minutes. Duration times were clearly non-normal, and control and αGBM groups 
were significantly different using a 2-tailed Mann-Whitney U test, P < 0.01. (E) Distributions using a 2-sample Kolmogorov-Smirnov (KS) test comparison 
percentile plot. The group duration time distributions were significantly different using a KS test, P < 0.01, D = 0.3813. (F) A bar graph of mean ± SEM is 
shown to provide a sense of scale for the dwell times. *P < 0.01 by 2-tailed unpaired t test.
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lar capillaries (Figure 6A, left panel, and Supplemental Video 4). In 
contrast, tracks in the anti-GBM–treated group were longer in dura-
tion and often had multiple periods of stable adhesion (Figure 6A, 
right panel, and Supplemental Video 5). We compared the distribu-
tion of video-rate duration times in control and anti-GBM groups 
in a single optical plane (Figure 6B). Similar to the 3D time-lapse 
data (Figure 5D), duration time distributions were heavily skewed 
toward shorter-duration interactions, but these events were bet-
ter resolved. Control and anti-GBM groups were significantly dif-
ular slice per hour at steady state and after anti-GBM antibody 
injection, respectively. The fraction of crawling neutrophils out 
of all trafficking cells was less than 0.2% (Supplemental Figure 
4, D and E, and Supplemental Video 3).
In order to better characterize the dynamics of the short-dura-
tion neutrophil–vessel wall interactions in glomeruli, we imaged in 
a single optical plane at high temporal resolution (40 ms per frame) 
(Figure 6, A–I). Individual cell tracks in glomeruli of control mice 
were brief and had few periods of stable adhesion within glomeru-
Figure 6. Analysis of short-duration neutrophil–vessel wall interactions in control and anti-GBM–treated LysM-GFP mice. In vivo 2-photon video-rate imaging 
of glomeruli in untreated LysM-GFP mice (Ctrl) (n = 3 mice, 5 glomeruli) and in LysM-GFP mice 1.5–2 hours after anti-GBM (αGBM) treatment (n = 3 mice, 4 
glomeruli). (A) A video-rate image of steady-state neutrophil (green) trafficking behavior in glomerular capillaries (red, Q-dot 565) (white arrows) of a control 
mouse (left panel) and a mouse after αGBM treatment (right panel). Images are 20 seconds of video-rate frames overlaid to show neutrophil tracks (green) in 
glomerular capillaries (red, Q-dot 565). Scale bars: 25 μm. (B) Distributions of cell dwell times in a single plane from video-rate recordings of control and αGBM 
mice plotted in seconds. Duration times were significantly different between the groups using a 2-tailed Mann-Whitney U test, P < 0.001. (C) Distributions using 
a 2-sample KS test comparison percentile plot. Group dwell time distributions were significantly different, P < 0.001, D = 0.6970. (D and E) Neutrophil velocities 
were plotted over time and fit to a hidden Markov 2-state model (HMM 2-state) to identify cell track transitions from fast moving, state 1 (S1), to adherent, 
state 2 (S2), behavior. Two representative cell tracks (1 and 2) from the control group (D) with typical steady-state behavior showed fluctuations in cell velocity, 
but no S1 to S2 transition, while those from the αGBM group (E) made brief S2 transitions (left panel) and sustained S2 transitions (right panel). (F) Mean dwell 
time ± SEM in seconds from video-rate recordings in control and αGBM groups. (G) Average S1 to S2 transition frequency per track in control and αGBM groups. 
S2 transitions were more frequent in the αGBM group. (H) Average S2 durations were more prolonged in the αGBM compared with the control group. (I) Average 
neutrophil S1 velocities (μm/s) were higher in the control versus the αGBM group. *P < 0.01, **P < 0.001, by 2-tailed unpaired t test for F–I.
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Figure 7. Rapid neutrophil capture in glomerular capillaries is FcγRIIA and Abl/Src dependent. (A–F) FcγRIIA+/γ–/– recipient mice were given anti-GBM 
antibody (αGBM) (A–C) or left untreated (D–F), and 2-photon time-lapse imaging of the kidney was conducted 2 hours later following the simultaneous 
adoptive transfer of FcγRIIA+/γ–/– (IIAγ–/–) and γ–/– neutrophils differentially labeled with green or blue fluorescent dye and a red dextran vascular dye. Dura-
tion times were calculated as the time in seconds that neutrophils remained arrested in the capillary and the distribution of dwell times plotted as histo-
grams. (A–C) In αGBM-treated recipients given IIAγ–/– and γ–/– neutrophils, the group and dwell time distributions were compared using a Mann-Whitney U 
test (A, P < 0.001), a 2-sample KS test comparison percentile plot (B, P < 0.001, D = 0.2485), and a 2-tailed unpaired t test (C, *P < 0.001) (n = 4 recipient 
mice with n = 2 for each neutrophil dye combination, 33 glomeruli). (D–F) Untreated recipients were analyzed following the adoptive transfer of labeled 
IIAγ–/– and γ–/– neutrophils, and statistics were conducted as in A–C (D, P = 0.138; E, P = 0.138, D = 0.1859; F, P = 0.138) (n = 3 recipient mice with 1 dye 
combination, 21 glomeruli). (G–I) FcγRIIA+/γ–/– recipient mice were given αGBM, and time-lapse imaging was conducted 2 hours after the adoptive transfer 
of differentially labeled FcγRIIA+/γ–/– neutrophils pretreated with 100 nM bosutinib (Bos) or vehicle (DMSO). Duration time (seconds) and group dwell time 
distributions were compared as in A–C. Statistics are as follows: G, P < 0.001; H, P < 0.001 and D = 0.2346; I, *P < 0.001 (n = 4 recipient mice with n = 2 for 
each neutrophil dye combination, 22 glomeruli). Bar graphs in C, F, and I are mean duration time ± SEM in seconds.
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earliest steps of neutrophil recruitment. The early, subsecond 
adhesive events that we describe herein may precede the previous-
ly reported glomerular intraluminal crawling behavior (ref. 40 and 
Supplemental Figure 4).
Rapid neutrophil capture within glomerular capillaries is depen-
dent on FcγRIIA and inhibited by bosutinib. Our single-cell analysis 
shows that when anti-GBM antibody is deposited, the frequency 
of S2 stable interactions increases, as does the average duration of 
S2 adhesion events (from <0.25 in the steady state to ~1.6 seconds 
in the anti-GBM treatment group). Our video-rate analysis using 
KS percentile plots suggests that IgG-mediated capture events 
primarily occur on this short-duration time scale (subsecond to 
second), while longer cell retention times on the order of minutes 
are likely to involve other cell adhesion mechanisms. Based on this 
duration window, we evaluated the role of FcγRIIA in neutrophil 
binding using a time resolution of 0.42 seconds, which should 
be sufficient to document the majority of Fc-mediated capture 
events. Moreover, we evaluated a potential cell-autonomous role 
for human FcγRIIA in the capture of neutrophils using adoptive 
transfer approaches: FcγRIIA+/γ–/– recipient mice were given an i.v. 
injection of rabbit anti-GBM antibody, and 1.5 hours later injected 
i.v. with differentially labeled, fluorescent FcγRIIA+/γ–/– and γ–/– 
bone marrow–derived mature neutrophils, which allowed for the 
analysis of 2 defined cell populations in the same glomerulus. The 
kidney was then surgically exteriorized, glomeruli were imaged, 
and neutrophil duration times in a single optical plane were eval-
uated. We observed a statistically significant difference in the dis-
tribution of neutrophil duration times between FcγRIIA+/γ–/– and 
γ–/– neutrophils (Mann-Whitney U, P < 0.001) (Figure 7A). Neutro-
phil duration time was also analyzed using a KS test comparison 
ferent (2-tailed Mann-Whitney U, P < 0.01), with the anti-GBM 
group having more frequent stable events lasting several seconds 
(Figure 6B). The duration time distributions were also compared 
using a 2-sample KS test, and the percentile plot showed that the 
distributions diverged early and the maximum difference was in 
the subsecond range (P < 0.001, D = 0.6970) (Figure 6C). To better 
describe neutrophil retention behavior, we used a hidden Markov 
2-state model (HMM 2-state) to evaluate neutrophil transitions 
from state 1 (S1; irregular flowing behavior) to state 2 (S2; transient 
adhesion behavior). In control mice, cell velocity varied over time, 
but transitions to S2 were rare and cells typically passed through 
the field of imaging displaying S1 behavior (Figure 6D). In contrast, 
neutrophil tracks in the anti-GBM–treated group often contained 
abrupt transitions from S1 to S2, indicating that cells were actively 
binding to the vessel wall (Figure 6E, left panels). Transient bind-
ing events were frequent, but in some cases, adhesive interactions 
lasted for the duration of the recording (Figure 6E, right panels). 
Tracks in the anti-GBM group had significantly increased mean 
duration times (Figure 6F). Furthermore, adhesive interactions (S2 
transitions) were more frequent in the anti-GBM group, occurring 
approximately once on average per track (Figure 6G), and S2 adhe-
sive events were longer in duration in comparison with the control 
group (Figure 6H). S1 velocities were higher in the control group 
than in the anti-GBM group (Figure 6I), possibly as a result of more 
frequent upstream S2 events in the latter. Neither group displayed 
sustained classic selectin-mediated rolling behavior reported in 
larger vessels, which is substantially slower and may not occur in 
narrow glomerular capillaries as it requires changes in shear stress 
in the midline versus the vessel wall. Notably, the short duration 
of our video-rate imaging experiments was designed to catch the 
Figure 8. Bosutinib attenuates renal neutrophil accumulation and injury in crescentic anti-GBM nephritis. FcγRIIA+/γ–/– mice preimmunized at day –3 were 
injected i.v. with anti-GBM (αGBM) serum at day 0. Bosutinib (Bos, 150 mg/kg) or vehicle (Veh) was administered by gavage every 24 hours from day 0 to day 21. 
(A) Urine albumin normalized to creatinine was determined. (B) The kidneys were harvested at day 21. Representative images of renal sections and histological 
scores are shown. PAS, periodic acid–Schiff. Scale bar: 100 μm. n = 8–15 mice per group in A and B. (C) Glomerular (glm) neutrophil accumulation in anti-neutro-
phil antibody–stained renal sections was quantitated. n = 3 for vehicle and n = 4 mice for bosutinib. *P < 0.05, **P < 0.01, by 2-tailed unpaired t test.
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neutrophils suggests that neutrophils may circumferentially inter-
act with IgG deposits as they pass though. This unconventional 
IgG-mediated neutrophil capture occurs via FcγRIIA and is an 
active process, as bosutinib, an inhibitor of Abl/Src kinases, mark-
edly inhibited the number and duration of capture events both 
in vitro and in vivo. Mechanistically, these capture events may 
be facilitated by Abl1/Src kinase regulation of F-actin polymer-
ization, which strengthens FcγR-IgG interactions when the cells 
experience mechanical force, as may be the case when neutro-
phils transit through glomerular capillaries. Intravital microscopy 
analysis suggests that captured neutrophils may be released into 
circulation after transient interaction or sustain adhesion. The 
latter could trigger the intravascular generation of ROS, proteas-
es, and NETs, which could promote glomerular damage (40, 42, 
43). Bosutinib’s inhibition of IC-mediated cytotoxic functions 
in vitro suggests that it may both reduce neutrophil recruitment 
and dampen neutrophil cytotoxicity in vivo. Accordingly, in an 
experimental model of proliferative, crescentic anti-GBM nephri-
tis, bosutinib significantly averted FcγRIIA-mediated neutrophil 
accumulation and glomerular injury.
Intravital microscopy revealed that neutrophils make brief, 
subsecond interactions with the endothelium in the steady state, 
presumably due to irregular hydrodynamic flow through the 
small-diameter and tortuous glomerular capillary bed. However, 
following anti-GBM deposition, the frequency of stable interac-
tions increased, as did the average duration of adhesion events. 
FcγRIIA on neutrophils played a significant, cell-autonomous role 
in the rapid capture of neutrophils following anti-GBM antibody 
deposition, suggesting that FcγRIIA participates in one of the ear-
liest steps of autoimmune-mediated neutrophil accumulation in 
the kidney. Binding of cells under shear requires the rapid forma-
tion of longer-lived adhesive bonds called catch bonds that resist 
shear-induced detachment forces of flowing blood; catch bonds 
have been shown to occur with selectin/ligand pairs, which are 
known to promote neutrophil capture and rolling (44, 45). We 
demonstrate that FcγRIIA-IgG forms catch bonds in vitro that 
may be reflected in vivo in the subsecond transition of flowing 
neutrophils to arrest in the presence of anti-GBM antibody. The 
observed frequent FcγRIIA-mediated neutrophil interactions with 
anti-GBM antibody within capillaries may lead to CD18 integrin 
activation and thus substitute for selectin-mediated rolling, which 
facilitates integrin-mediated firm adhesion (46). Indeed, activat-
ed Mac-1 sustains FcγR-mediated neutrophil adhesion under stat-
ic and flow conditions (10, 21, 22) and following acute anti-GBM 
nephritis (21, 40). Interestingly, Mac-1 activation by ICs but not 
GPCR agonists (e.g., FMLP) relies on actin polymerization (47), 
which suggests the possibility that F-actin polymerization, essen-
tial for FcγR-mediated neutrophil capture and for catch bond for-
mation in vitro, may concurrently promote Mac-1 activation.
Although the molecular mechanisms driving FcγR-mediat-
ed neutrophil cytotoxic functions such as phagocytosis and ROS 
generation are relatively well defined (48, 49), those that support 
FcγR-mediated neutrophil capture by ICs were unknown. Our 
studies revealed a role for Abl/Src in rapid neutrophil capture by 
ICs under flow conditions. The significant effect of Abl1 silencing 
on FcγRIIA-mediated neutrophil capture and F-actin polymeriza-
tion contrasts with the partial effects of silencing Abl family mem-
percentile plot (Figure 7B), which showed group duration time dis-
tributions that were significantly different (P < 0.001, D = 0.2485) 
with FcγRIIA+/γ–/– neutrophils having increased mean duration 
times compared with γ–/– (Figure 7C). The observed binding defect 
in injected γ–/– neutrophils despite the presence of FcγRIIA+/γ–/– 
neutrophils demonstrates cell-autonomous roles for FcγRIIA in 
neutrophil recruitment. Notably, there was no difference in the 
distribution of duration times between FcγRIIA+/γ–/– and γ–/– neu-
trophils injected into untreated recipient mice (Figure 7, D–F).
To evaluate the role of Abl/Src in FcγRIIA-dependent recruit-
ment, FcγRIIA+/γ–/– neutrophils were pretreated with either bosu-
tinib or vehicle control ex vivo, differentially labeled, and adop-
tively transferred into FcγRIIA+/γ–/– recipient mice given anti-GBM 
antibody. Bosutinib treatment significantly altered neutrophil 
duration time distributions in glomerular capillaries compared 
with vehicle-treated counterparts (Mann-Whitney U, P < 0.001; 
KS test, P < 0.001, D = 0.2346) (Figure 7, G and H) and reduced 
the mean neutrophil duration time (Figure 7I and Supplemental 
Video 6). As observed in LysM-GFP mice, adoptively transferred 
neutrophils were rapidly captured in the absence of prior rolling or 
crawling (Supplemental Video 6).
Bosutinib inhibits neutrophil accumulation and glomerular inju-
ry in a model of proliferative GN. Neutrophil accumulation is asso-
ciated with glomerular injury in rapidly progressive, proliferative 
crescentic anti-GBM nephritis in patients (5). This is modeled in 
mice by the administration of anti-GBM antibody and preimmu-
nization with Freund’s adjuvant and rabbit IgG, which leads to GN 
over a period of 14–21 days. Neutrophil influx and injury in this 
model is neutrophil FcγRIIA dependent (9). We first established 
an effective in vivo dose of bosutinib in mice. Four hours after 
gavage of 150 mg/kg bosutinib (41), peripheral blood neutrophils 
from mice exhibited a reduction in FcγRIIA cross-linking–induced 
ROS generation ex vivo (Supplemental Figure 5A). This dose also 
prevented the acute, cutaneous reverse passive Arthus reaction 
(Supplemental Figure 5, B and C) induced by the i.v. injection 
of BSA and the s.c. injection of anti-BSA antibody. Next, FcγRI-
IA+/γ–/– mice were subjected to crescentic, anti-GBM nephritis and 
given a daily gavage of bosutinib or vehicle over a 21-day period. 
Bosutinib markedly reduced albuminuria (Figure 8A), crescent 
formation, tubulointerstitial injury (Figure 8B), and glomerular 
neutrophil accumulation (Figure 8C) despite normal deposition 
of anti-GBM antibody (Supplemental Figure 5D) and peripheral 
blood leukocyte counts (Supplemental Figure 5E). Although sys-
temic administration of bosutinib may affect several cell types, 
our previous finding that FcγRIIA expression on neutrophils can 
restore glomerular neutrophil influx and injury in γ–/– mice sub-
jected to crescentic anti-GBM nephritis (9) suggests that bosutinib 
reduced disease primarily by targeting FcγRIIA on neutrophils in 
FcγRIIA/γ–/– animals.
Discussion
Our studies show that unlike the hierarchical cascade of neutro-
phil recruitment described in postcapillary venules that begins 
with rolling and subsequent adhesion of neutrophils to the acti-
vated endothelium, IgG-IC deposition within glomerular capil-
laries directly recruits neutrophils via their FcγRIIA. Moreover, 
the observation that glomerular capillaries are similar in size to 
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In summary, our studies have revealed a new pathway of 
neutrophil recruitment in the glomerulus that depends on FcγRI-
IA-mediated neutrophil capture by IgG deposited within glomer-
ular capillaries. This may occur through FcγRIIA-mediated Abl1 
and Src kinase–induced F-actin polymerization, which in turn may 
strengthen FcγRIIA-IgG interactions under flow conditions. We 
also provide evidence that bosutinib, currently used for the treat-
ment of CML (65), averts this very early step in glomerular inflam-
mation and may thus potentially be repurposed for Goodpasture’s 
syndrome and possibly other proliferative GN.
Methods
Mice. Human FcγRIIA–expressing, γ chain–deficient (FcγRIIA+/γ–/–) 
mice and FcγRIIA-expressing, γ chain–deficient mice were as previ-
ously described (9, 66). These mice were maintained in a virus- and 
antibody-free facility at the New Research Building animal housing 
facility at Harvard Medical School. Mice used for each experiment 
were 8–10 weeks of age and were age- and sex-matched. LysM-GFP 
mice were provided by Klaus Ley (La Jolla Institute for Allergy and 
Immunology, La Jolla, California, USA), who backcrossed the original-
ly generated mice from T. Graf (Albert Einstein College of Medicine, 
Bronx, New York, USA) to the B6 background. These mice were main-
tained and bred under specific pathogen–free conditions at Washing-
ton University School of Medicine. The Harvard Medical Association 
IACUC at Harvard Medical School approved all animal experiments.
Neutrophil ROS-based high-throughput small-molecule screen. In 
collaboration with the Institute of Chemistry and Cell Biology Screen-
ing facility at Harvard Medical School (ICCB-Longwood), 8,483 com-
pounds were screened. Details are in Supplemental Methods. For a 
secondary screen, serial dilutions of the 30 top-ranked compounds 
that suppressed ROS generation were tested on a single 384-well plate 
using the same protocol as the primary screen. Reagents for subse-
quent studies were as follows: cytochalasin D and PP2 from Sigma-Al-
drich and bosutinib (B1788), imatinib (I5508), and nilotinib (N8207) 
from LC Laboratories.
Human neutrophils, mouse bone marrow neutrophils, and HL-60 
cells. Human polymorphonuclear neutrophils (>95% pure) were iso-
lated from whole blood drawn from healthy volunteers as previously 
described (67) under Partners IRB approval (protocol 1999P001694). 
Mouse bone marrow neutrophils (BMNs) were isolated by Per-
coll gradient separation. HL-60 cells (ATCC) were cultured in 
RPMI 1640 supplemented with 10% FBS, l-glutamine, and peni-
cillin/streptomycin. The cells were differentiated into neutrophils 
with 0.8% dimethylformamide (DMF; Sigma-Aldrich) for 4 days. 
Sequence-verified shRNA lentiviral plasmids against Abl1 (Mission 
library, Sigma-Aldrich, TRCN0000121100 and TRCN0000121101) 
were used to produce lentiviral particles in HEK293 T cells (clone 
17, ATCC) by standard methods. Undifferentiated HL-60 cells were 
transduced with lentiviral shRNA particles, cultured for 5 days, 
selected for 10 days with 10 μg/ml puromycin, and differentiated for 
an additional 4 days with DMF.
Human CML blood samples. Anticoagulated blood samples (collect-
ed in citrate buffer) were obtained from 3 patients on 200, 400, or 500 
mg/d bosutinib and age-, sex-, and ethnicity-matched normal volun-
teers. The blood was subjected to 2–3 sequential rbc lysis steps using 
ammonium-chloride-potassium (ACK) lysis buffer, resuspended in 
PBS at 1 × 107 cells/ml, and adjusted to 1 × 106 cells with RPMI plus 0.1% 
bers on other myeloid functions (50, 51) such as FcγR phagocytosis 
(50), and emphasizes the bias in signaling pathways in different 
myeloid functions. Bosutinib also inhibited FcγR-mediated cyto-
toxic functions, which is consistent with a study using a related 
Abl/Src inhibitor, dasatinib, though in this case IC-mediated ROS 
generation and granule release were evaluated only under adhe-
sion-dependent conditions (52), which are both FcγR and Mac-1 
dependent (21). We specifically placed Abl1 kinases downstream of 
FcγRIIA by examining bosutinib’s effects after cross-linking FcγRI-
IA in suspension, by treating neutrophils with other Abl inhibitors 
that do not affect Src kinases, and by Abl1 silencing. Abl1 silencing 
did not affect bolished FcγRIIA-induced F-actin polymerization. 
Src inhibition also affected F-actin polymerization, suggesting 
the possibility that Abl and Src kinases are in the same pathway. 
Indeed, Src kinases may tyrosine-phosphorylate Abl1 to stabilize 
Abl’s active conformation (54). On the other hand, the 2 kinases 
could act in parallel, as Src may contribute to the activation of PI3K, 
FAK–Pyk-2 kinases, and Vav that feed into the Rho GTPase–WASP 
pathway of actin polymerization (53), while Abl1 may directly bind 
F-actin and/or phosphorylate cytoskeletal proteins that regulate 
actin polymerization (19). Surprisingly, while actin polymeriza-
tion was essential for FcγRIIA-mediated cell capture on ICs under 
shear flow, it was largely dispensable for cell attachment to ICs 
under static conditions. Shear changes the biophysics of adhesion, 
as it requires the rapid formation of longer-lived adhesive bonds 
called catch bonds that resist shear-induced detachment forces 
(45). Indeed, catch bonds may increase neutrophil “on” rates while 
decreasing “off ” rates and thereby increase neutrophil capture in 
the glomerulus following anti-GBM deposition.
The efficacy of bosutinib in reducing IgG-mediated glomer-
ular neutrophil recruitment and associated injury suggests the 
possibility of repositioning this drug for the treatment of IgG-me-
diated proliferative GN, which has significant unmet clinical need 
(1, 55, 56). Glomerular IC deposition and neutrophil accumulation 
contribute to the pathogenesis of Goodpasture’s syndrome (anti-
GBM disease) and acute poststreptococcal nephritis, which is a 
risk factor for subsequent development of chronic renal failure (1, 
2). Neutrophils also accumulate in proliferative lupus nephritis (3), 
with recent transcriptional profiling of blood from lupus patients 
showing a gradual enrichment of neutrophil transcripts during 
progression to active nephritis (57). Reducing the renal burden 
and cytotoxic function of neutrophils may also preserve long-term 
kidney function by dampening intrarenal autoimmunity in pre-
disposed individuals (3, 58, 59). As with other compounds in the 
Bcr-Abl class of inhibitors, bosutinib can also target other kinases 
such as salt-inducible kinases and TEC-family kinases (32) and 
very likely has antiinflammatory effects beyond the inhibition of 
FcγRIIA and neutrophils (60, 61). On the other hand, Src inhibi-
tion could promote dendritic cell activation as shown in vitro with 
dasatinib (62) or lead to lupus-like symptoms as reported in mice 
with B cell deficiency in the Src kinase Lyn (63). Indeed, the choice 
of Abl inhibitors may be important in limiting certain unwanted 
effects. For example, unlike dasatinib, bosutinib does not mobi-
lize cytotoxic lymphocytes (64). Notably, bosutinib is a relatively 
well-tolerated drug (16). The serious adverse events are primarily 
early-onset gastrointestinal toxicity, mainly diarrhea, nausea, and 
vomiting that were low-grade, transient, and manageable (16).
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Biomembrane force probe experiments. The biomembrane force 
probe technique has been previously described (69). In a chamber filled 
with L15 buffer with 1% BSA and 1 mM Ca2+/Mg2+, a hIgG1/streptavidin 
bead was attached to the apex of a micropipette-aspirated biotinylat-
ed rbc, which together acted as an ultrasensitive force transducer. The 
aspiration pressure was set to control the probe stiffness at 0.2 or 0.3 
pN/nm, based on calculations (70). The axial displacement of the bead-
rbc interface was monitored by high-speed camera, which reflected the 
force on the rbc by Hooke’s law. Jurkat cells lacking CD18 integrins (36), 
provided by Timothy A. Springer (Harvard Medical School, Boston, 
Massachusetts, USA), were engineered to express FcγRIIA. The Jur-
kat-FcγRIIA–expressing cell was then aspirated by an opposing micro-
pipette and driven by a piezo actuator with subnanometer spatial preci-
sion. The Jurkat cell was programmed to approach and briefly interact 
with the probe bead to allow bond formation, which was signified by a 
tensile force on the rbc upon retraction of the cell. Following that, dis-
tance clamping was performed to measure the lifetime of this bond 
under a certain force. After dissociation of the bond, the cell was retract-
ed to the original position to wait for the next cycle. To measure the bond 
lifetimes under zero force, after touching the bead, the Jurkat-FcγRIIA–
expressing cell was retracted to the zero-force position and then held 
stationary. Bond association/dissociation was manifested as a sudden 
drop/increase in the thermal fluctuations of the bead position, which 
was quantified by the average standard deviation of a sliding interval of 
70 time points (71). The site density of the hIgG1 was titrated to keep the 
adhesion frequency approximately 20%, to ensure that approximately 
90% of adhesion events were mediated by single bonds. As a confirma-
tion of the binding specificity, beads coated with streptavidin alone con-
tacting the same batch of Jurkat cells only rendered approximately 3% 
adhesion frequency. For experiments with cytochalasin D, Jurkat-ex-
pressing FcγRIIA cells were incubated with 20 μM of cytochalasin D for 
30 minutes under 37°C before being placed into the chamber.
Two-photon intravital microscopy of the glomerulus. FcγRIIA+/γ–/– iso-
lated mouse BMNs (1 × 107) were stained with Cell Tracker Green CMF-
DA or Cell Tracker Blue CMF2HC (5 μM; Life Technologies), washed 
with PBS, and incubated with 100 nM bosutinib or DMSO vehicle, 
respectively, at 37°C for 30 minutes. A recipient FcγRIIA+/γ–/– mouse 
was given anti-GBM serum, and labeled neutrophils were transferred 
i.v. Alternatively, LysM-GFP reporter mice were given anti-GBM serum 
to image endogenous neutrophil trafficking during glomerular injury 
and in some cases additionally given a retro-orbital injection of 3.5 μg 
of PE–anti-Ly6G antibody (clone 1A8, eBioscience). The right kidney 
of the mouse was surgically exteriorized 1.5 hours later and prepared 
for intravital microscopy, which took 30 minutes. Details for intravital 
microscopy imaging are in Supplemental Methods. Glomerular lumen 
diameter was measured manually in z-sections using the Imaris 8.2 line 
measurement tool. The diameter of LysM-GFP neutrophils in glomer-
ular capillaries was measured along the smaller axis. For all intravital 
microscopy experiments, 2 or more glomeruli were analyzed per mouse.
Two-photon imaging data analysis and the HMM 2-state model. Veloc-
ities were plotted over time and fit to an HMM 2-state plot. The rationale 
for using an HMM 2-state model stems from the fact that neutrophils 
do not flow smoothly through glomerular capillaries in the steady state. 
This unusual behavior may in part be due to irregularities in hydrody-
namic flow in small tortuous vessels, interactions with other cells in the 
capillaries, or adhesive interactions independent of FcγRs. The HMM 
2-state model allows us to discriminate fluctuations in velocity and tran-
BSA before experiments. Aliquots were evaluated by FACS analysis for 
FcγRIIA expression using anti-CD32 FITC (555448, BD Biosciences). 
Granulocytes were identified by forward scatter and side scatter.
FcγR cross-linking–induced generation of ROS, neutrophil degranu-
lation, and Western blot analysis. Additional details and the complete 
unedited Western blots are provided in the supplemental materials.
Adhesion and spreading assay under static conditions. The adhesion 
assay and F-actin staining were as previously described (21). Briefly, 
neutrophils were plated on glass coverslips coated with BSA and anti-
BSA (B7276, Sigma-Aldrich), and coverslips were fixed 20 minutes lat-
er. Adherent cell numbers were quantitated in 3 independent fields at 
magnification ×200, and the average cell number per field was deter-
mined. Cells were stained with Alexa Fluor 568 phalloidin, the area of 
a single spread cell was calculated with ImageJ (NIH), and the values 
of 20 cells were averaged.
Adhesion assay under shear stress. For binding assay on ICs, cover-
slips were coated with BSA or preformed soluble ICs of BSA–anti-BSA 
for 2 hours at room temperature, which were generated as previously 
described (10, 68). Coverslips were mounted on a flow chamber, and 
cells were perfused for 4.5 minutes at the indicated shear stresses. Live 
imaging of cell adhesion was recorded with a video camera on a Nikon 
TE2000 inverted microscope equipped with a 20× 0.75 NA phase 
contrast objective and VideoLab software (Mitov).
Human dermal microvascular endothelial cells (HDMECs) 
(HMVEC-D, Lonza) were grown to confluence on fibronectin-treat-
ed glass coverslips and activated with human TNF-α (10 ng/ml) for 4 
hours where indicated. ECs were incubated with mouse anti-endog-
lin mAb (anti-CD105, clone 43A3, BioLegend) for 15 minutes at 37°C, 
gently washed, and subsequently incubated with rabbit anti-mouse 
IgG (1:250 dilution) for 15 minutes. HDMECs were assembled into 
a parallel plate flow chamber maintained at 37°C. Human peripher-
al PMNs were purified from freshly drawn blood and incubated with 
anti-FcγRIIIB (clone 3G8, BioLegend), anti-FcγRIIA (clone IV.3, Stem-
cell Technologies), appropriate isotype (Iso) controls or bosutinib 
(100 nM), imatinib (100 nM), or cytochalasin D (20 μM) for 30 min-
utes at 37°C. The human PMNs were diluted 10-fold to 106 cells/ml 
and drawn across the endothelial cell layer at 1.5 dyn/cm2. For all flow 
experiments, the number of cells that accumulated in 4 fields in each 
coverslip was calculated and averaged. For each independent experi-
ment, 2 coverslips were evaluated per condition and averaged.
Flow cytometric analysis of F-actin polymerization. 10 × 106 HL-60 
cells/ml in PBS were incubated with 10 μg/ml mouse anti-hFcγRIIA 
(clone IV.3, Stemcell Technologies) and thereafter stained with Zombie 
Aqua (423102, BioLegend) on ice for 20 minutes. After washing, cells 
were incubated with 1 ng/ml human GM-CSF (R&D Systems) in PBS 
with Ca2+/Mg2+ at 37°C for 15 minutes and pretreated with indicated 
reagents at 37°C for 30 minutes. Goat anti-mouse F(ab′)2 (36 μg/ml; 112-
006-072, Jackson ImmunoResearch) was added to induce cross-link-
ing, and the reaction was stopped with ice-cold 1.5% PFA solution at 
4°C for 30 minutes. After permeabilization with 0.1% saponin (Sigma- 
Aldrich) for 2 minutes at room temperature, cells were stained with 
NBD-phallacidin (Life Technologies) at 4°C for 20 minutes, and the flu-
orescence signal intensity was analyzed with a DxP12 Analyzer (Cytek).
rbc and hIgG1/streptavidin bead preparation for biomembrane force 
probe experiments. Human rbc were isolated from whole blood and bioti-
nylated as previously described (69), and hIgG1/streptavidin–coated 
beads were prepared as detailed in Supplemental Methods.
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For other data, statistical differences were analyzed with the unpaired 
2-tailed t test. P less than 0.05 was considered significant. For statis-
tical analysis of data presented as fold induction, an average of data 
from control samples is assigned a value of 1, and all data are calculat-
ed relative to this value.
Study approval. The Harvard Medical School Animal Care and Use 
Committee approved all procedures in this study. Human peripheral 
blood was obtained from healthy volunteers under a protocol approved 
by the Brigham and Women’s Hospital IRB, and all subjects gave writ-
ten informed consent. Blood samples from CML patients were obtained 
under a Dana-Farber Cancer Institute IRB-approved protocol.
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sitory adhesive interactions that are common in the steady-state neutro-
phil behavior (defined as S1 behaviors) from bona fide FcγR-dependent 
binding events in anti-GBM–treated mice. We used the HMM 2-state to 
assign cell decelerations from S1 as coming from the “hidden state” (i.e., 
S2) when track speed drops below ≤50 μm/s for 2 consecutive frames, 
which filters out steady-state fluctuations and respiration artifacts. S2 
was defined as a genuine binding interaction and presumably occurred 
as a result of FcγR catch bond formation. Track durations were obtained 
and plotted to demonstrate the number of cells at time intervals of 0.56 
seconds for each group. Average velocities per individual track from con-
trol and anti-GBM groups were calculated, along with the average dura-
tion spent in each state (S1, S2). In order to demonstrate the difference 
in neutrophil behavior between the control and anti-GBM, the average 
frequency of neutrophil adhesion in kidney glomeruli was plotted. The 
mean ± SEM or median ± median absolute deviation was calculated for 
distributions as descriptive statistics, and reported for non-normal dis-
tributions to provide a rough value for discussion. Group distributions 
were plotted as histograms, and non-normal data were compared using 
a nonparametric 2-tailed Mann-Whitney U test where a confidence 
interval of 95% was used to determine statistical significance. In addi-
tion, a 2-sample Kolmogorov-Smirnov (KS) test was performed to com-
pare non-normal distributions. The KS test identifies distances between 
distributions, and the maximum distance (D) is shown to asymptotically 
converge to a statistical distribution of the exponential family and thus 
can assign a probability that the 2 distributions are equivalent. The max-
imum distance D is reported for each test, and the P value associated 
with the distance is also reported; a confidence interval of 95% was used 
to determine statistical significance.
Cutaneous reverse passive Arthus reaction. The reverse passive 
Arthus reaction was induced in the dorsal skin, and neutrophil accu-
mulation and edema were evaluated as we have described (72). Details 
are provided in the Supplemental materials.
Nephritis model. Proliferative, crescentic anti-GBM glomerulonephritis 
was induced and neutrophil accumulation and renal injury were evaluated 
as we have described (73). Details are provided in Supplemental Methods.
Statistics. All in vitro data and in vivo disease models are present-
ed as the mean ± SEM. One-way ANOVA followed by Dunnett’s test 
was used for multiple comparisons. Kidney histology scoring and infil-
trated neutrophil counts were compared by the Mann-Whitney U test. 
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